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Studies have proven that once there is greater control 
of hypertension, the attendant costs associated with 
its complications will fall.4-7 In developing economies 
such as Malaysia where the majority of patients fall 
under public health care with finite annual budgets, 
greater emphasis should be placed on the control of 
hypertension. 
There are several methodologies for evaluating pat-
terns of drug use and its attendant cost.8 A quick and 
inexpensive method is a simple audit of the annual 
antihypertensive expenditure and the number of pre-
scriptions given out. Data thus collected not only re-
flects on the prescribing habits of physicians but can 
also be used to assess the cost-effectiveness of the 
therapies used.8 In our study, we evaluated the total 
number of drug prescriptions given out in one year, 
the incurred expenditure and factored the two to 
give an annual (2006) cost per drug per person.
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ABSTRACT
Introduction: Hypertension is one of the most important risk factors for cardiovascular disease 
in Malaysia. The prevalence of hypertension nearly doubled over a ten-year period (1986 – 1996). 
This has resulted in a significant rise in its attendant cost. We aim to review the institutional 
anti-hypertensive use, the cost incurred and the implications on management in our local setting. 
Materials and Methods: A retrospective review of the annual cost (2006) of anti-hypertensive 
medications was undertaken at the Department of Pharmacy, Hospital Tengku Ampuan Afzan, a 
600-bed major regional hospital on the east-coast of Malaysia. The total number of prescriptions 
given out and the total cost per drug is then factored to give the annual cost per drug per person 
in a percentage of the total annual expenditure.Results: The majority of patients were on either 
2 (46.5%) or 3 (25.9%) anti-hypertensives. The most frequently prescribed medications were ACE 
Inhibitors (33.45%), Calcium channel blockers (29.63%), diuretics (16.67%) and β-blockers (13.64%). 
In terms of cost however, the Calcium channel blockers constituted the greatest percentage of the 
annual anti-hypertensive budget (63.67%) compared to ACE Inhibitors at just 20.04% of the annual 
expenditure. The least costly group of drugs is the diuretic making up 16.67% of the total annual 
prescriptions but only constituting 1.23% of the annual cost. Conclusion: The majority of patients 
were on ACE Inhibitors and/or Calcium channel blockers. This has huge monetary implications as 
they represent a large proportion of the annual antihypertensive allocation. There may be a need 
to reverse the trend in the developing world due to cost restrictions.   
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INTRODUCTION
There is now an array of locally produced epidemio-
logical data on the rise of hypertension prevalence in 
Malaysia. Over a ten-year period, there has been a 
doubling in its prevalence from a mere 14.4% in 1986 
to 29.9% in 1997.1 This is expected to increase further 
with the publication of the latest figures from the Na-
tional Health and Morbidity Survey (2006). Although 
the data on hypertension control in the community 
is slightly fragmented, it does show a tiered pattern 
of progressively better control from the population 
study level (6%) to the public (26%) and private (59%) 
primary care clinics level.1-3    
The cost of hypertension to the community is two-
fold; first is the actual cost of the drug and this is 
tied to the prevalence of hypertension in the com-
munity, and second is the cost of managing the com-
plications associated with uncontrolled hypertension. 
MATERIALS AND METHODS
The study was conducted in a medical outpatient 
clinic at the Hospital Tengku Ampuan Afzan, Kuantan, 
Malaysia. Kuantan is the capital of the east-coast Pen-
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insular Malaysia state of Pahang which has a predomi-
nantly agrarian economy. It serves a population of one 
and a half million people, the majority of whom are 
looked after in the public health care sector in view 
of the lack of a comprehensive medical insurance 
policy in Malaysia. These patients pay a nominal flat 
fee which covers both the cost of consultation and 
treatment.
The anti-hypertensive agents were classified into 
seven major groups; α-blockers (Prazosin), centrally 
acting agents (Methyldopa), diuretics (Chlorothiazide, 
Frusemide, Spironolactone), β-blockers (Propanolol, 
Metoprolol, Atenolol, Bisoprolol, Carvedilol), calcium-
channel blockers (Nifedipine, Diltiazem, Amlodipine, 
Felodipine), Angiotensin converting enzyme (ACE) in-
hibitors (Captopril, Enalapril, Perindopril, Ramipril) 
and Angiotensin receptor (ARB) blockers (Losartan, 
Irbesartan, Valsartan, Telmisartan). Other drug class-
es such as the vasodilator Hydralazine was omitted 
due to its small utilisation.  
The Hospital Tengku Ampuan Afzan (HTAA) Formulary 
was used as a reference for drug cost. The total num-
ber of medications given out and the total amount 
expended for each medication per annum (2006) was 
obtained. The British National Formulary (BNF) was 
used as a reference for recommended dosage regi-
mens.9 The annual cost for each medication per per-
son was then derived in the national currency, Ringgit 
Malaysia – RM ( 1 USD = 3.4 RM )
Statistical analysis
Data for continuous, closely symmetrical variables 
were analyzed using standard descriptive methods 
to estimate means ± SD. The total number of tablets 
issued by the HTAA Formulary and the total cost ex-
pended was derived. The total number of tablets was 
then divided by the recommended daily dosage based 
on the BNF over 365 days (1 year) to give the aver-
age number of individual prescriptions per year ( e.g. 
10950 tablets ÷ 3 [t.i.d. dosage according to the BNF] 
÷ 365 = 10 individual prescription per annum ). From 
here the total cost is then divided over the number of 
annual individual prescription to give the cost of an 
individual prescription per year (e.g. RM 2,000.00 per 
year ÷ 10 = RM 200.00 per prescription per year). 
RESULTS
A total of 11,644.58 prescriptions were given out for 
the year 2006 at a total cost of RM 2,211,589.77 (USD 
1 = RM 3.4). The pattern of antihypertensive prescrip-
tion by different drug classes is illustrated in Figure 
1. The most commonly used antihypertensives were 
the Angiotensin-converting enzyme (ACE) inhibitors at 
33.46% followed by the Calcium-channel blockers at 
29.63%. 
The annualised numbers of individual prescriptions 
are detailed in Table 1. This is derived by dividing the 
total number of tablets with the common daily dos-
age requirement based on the British National For-
mulary over 1 year (eg Prazosin 344,000 tablets ÷ 3 
(t.i.d. dosing) ÷ 365 days = 314.15). The commonest 
medications to be utilised in order of frequency are 
Perindopril, Amlodipine, Frusemide, Metoprolol and 
Spironolactone, making up 68.26 % of the total num-
ber of annual prescriptions and incurring 76.24 % of 
the total annual budget (RM 1,686,182.91). 
The proportion of each individual drug class to the an-
nual antihypertensive budget is illustrated in Table 2. 
The two costliest drug classes are the Calcium-channel 
blockers (63.67 %) and the ACE inhibitors (20.05 %), 
together taking up 83.72 % of the total annual budget. 
When we compare the proportion of drug utilisation 
(annualised number of individual prescriptions – Table 
1, Column 5) against the proportion of drug cost (Table 
2, Column 5), it is evident that the least ‘economi-
cal’ or ‘cost-effective’ drugs are the Calcium-channel 
blockers. Despite only representing 29.63 % of the an-
nual prescriptions, they take up 63.67 % of the annual 
antihypertensive budget. The least costly class is the 
diuretic which supply 16.67 % of the prescriptions but 
garner a mere 1.23 % of the cost. This is better illus-
trated in Figure 2.
We then factored the total annual cost per drug to 
the total annual number of prescriptions (Total annual 
cost ÷ Total annual prescription = Total annual cost 
per prescription i.e. the cost in RM of each drug per 
prescription, per year). We have ranked it in the order 
of most expensive to least expensive and highlighted 
the 5 most frequently used anti-hypertensive medica-
tions (Table 3).
This figure does not represent the true cost as it is 
derived from the total annual (2006) tablets given out 
which is then averaged over the optimal dosage regi-
men according to the British National Formulary and 
then factored against the total annual expenditure. In 
reality some prescriptions may differ from the optimal 
dosage regimen e.g. Prazosin is optimally prescribed 
as a t.i.d. (3 x / day) dose, however in reality patients 
may be on b.i.d. (2 x / day) or q.i.d. (4 x / day) doses. 
This will result in a difference compared to the actual 
per tablet cost over one year.
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Figure 1. Pattern of anti-hypertensive prescription 
cost.
Figure 2. Comparison between the proportion of pre-
scription and cost for the 5 most used drug classes.
Figure 3. The difference in prices (in RM) between 
different drug combinations based on the annual cost 
per person (Table 3).
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Table 1. Number of individual prescriptions per annum for different drug classes
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Table 2. Cost of individual medications per annum for different drug classes
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cost limitations in a developing economy such as ours. 
This has not been borne out by this study however as 
the data shows that the more expensive ACEI and CCBs 
are most widely prescribed (63.09 %). There could be 
several reasons for this discrepancy. 
Firstly, the availability of recent data on ‘newer’ an-
tihypertensive agents such as ACEIs, ARBs and CCBs 
have added to the compelling evidence for their use 
in hypertension especially when associated with car-
diovascular disease (CVD) prevention.13 Secondly, the 
high prevalence of CVD (20-25 % of total in-hospital 
mortality in Malaysia) and diabetes mellitus in our 
population makes a compelling argument for the ini-
tiation of ACEI in these patients. Thirdly, wider use of 
diuretics and β-blockers could be limited by their po-
tential adverse effects on glucose tolerance, lipid me-
tabolisme, hyperuricaemia and sexual dysfunction.13-15 
Finally, the reduced human resource and limited con-
sultation time may have induced medical practitio-
ners to prescribe CCBs ahead of other more indicated 
medications in order to effectively reduce blood pres-
sure quickly.  
Implications on the cost of antihypertensives
In a recent survey on antihypertensive prescription 
patterns of 331 patients in the Cardiology outpatient 
clinic Hospital Tengku Ampuan Afzan, the mean sys-
tolic (SBP) and diastolic blood pressure (DBP) among 
Table 3. Annual cost per drug, per prescription
DISCUSSION
Pattern of antihypertensive prescription
In this audit, the most commonly used antihyperten-
sives were the Angiotensin-converting enzyme inhibi-
tors (ACEI) and the Calcium-channel blockers (CCB). 
This seems to reflect the prevailing trend in antihy-
pertensive prescription patterns around the world 
especially that of the United States (US).8 In the US 
there has been a reduction in the use diuretics and 
β-blockers followed by a corresponding rise in the 
use of ACEI and CCBs.8,10 This runs contrary to current 
recommendations on the use of antihypertensives in 
hypertension.4 
The Malaysian Clinical Practice Guidelines for the 
management of Hypertension which mirrors the World 
Health Organisation’s (WHO) recommendations close-
ly underlines the use of specific agents for particular 
compelling indications without which monotherapy 
with diuretics or β-blockers is suggested.11 The US 
guidelines also favor the use of thiazide diuretics in 
uncomplicated monotherapy for hypertension.12 The 
British guidelines have moved away from diuretics 
and incorporated the AB/CD concept in which those 
younger than 55 to initiate therapy with ACEI or ARB 
and those older than 55 to initiate CCB or diuretics.13
In Malaysia, the adoption of diuretics as the principle 
monotherapy in uncomplicated hypertension not only 
reflects the recommendations of other internationally 
available guidelines but also reflects the realities of 
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trend. These medications however take up the major-
ity of our annual antihypertensive budget and a true 
cost-effectiveness analysis need to be undertaken to 
ascertain the sustainability of this trend, its macro-
economic implications and whether the same level of 
blood pressure control could be achieved with cheap-
er alternatives.    
hypertensive patients was 139.3 ± 21.0 mmHg / 81.6 
± 10.4 mmHg and the majority of patients were on ei-
ther 2 (46.5%) or 3 (25.9%) antihypertensives. This has 
costly repercussions as, 24.17 % of patients were on 
both ACEI/ARB and CCBs and a further 67.67 % were 
on either ACEI/ARB or CCBs in combination with oth-
er medications. A staggering 91.54 % were on either 
ACEI/ARB and/or CCBs.16 
The cost of keeping a patient on an Amlodipine 10 mg 
and Perindopril 8 mg (based on the cost derived from 
Table 3) is RM 595.55 per annum. When compared to 
keeping the same patient on Perindopril 8 mg and 
Chlorothiazide 500 mg (RM 136.20) or Atenolol 100 mg 
and Chlorothiazide 500 mg (RM 68.00) the difference 
is almost exponential as illustrated in Figure 3. The 
implication is, for the same cost of keeping 1 person 
on an Amlodipine / Perindopril combination per an-
num, we can keep 8.7 persons on an Atenolol / CTZ 
combination or 4.4 persons on the Perindopril / CTZ 
combination per annum.
This is compounded by the fact that the median price 
ratio (MPR) for many drugs in Malaysia, including ge-
nerics are higher than the International Reference 
Price (IRP) across all sectors. Therefore, an unskilled 
government worker commanding the lowest pay in 
the public sector would require 4.9 days of wages 
to pay for 1 month treatment with Amlodipine 5 mg 
from private retail pharmacies.17 This is offset by the 
fact that most patients are managed under the pub-
lic health service with nominal fees for consultation, 
treatment and medications. However the implication 
on the burgeoning annual health budget will be tre-
mendous.
Recommendations
The rationale for making a particular selection when 
initiating antihypertensive therapy should as in any 
other aspect of medicine, be evidence-based and 
clinically impartial. Increasingly however, the cost-re-
lated implication of treatment is having an impact on 
the choice made by physicians especially in resource-
poor or developing economies with publicly funded 
health care. 
Insofar as this consideration does not run contrary to 
the prevalent volume of evidence or guidelines, this 
consideration should not only be accepted but pro-
moted to ensure optimal population coverage. When 
these considerations do collide, measures need to be 
put in place in order to limit the macroeconomic im-
pact. In our practice, a true cost-effectiveness analy-
sis should follow before any changes to the current 
CPGs are implemented. This is due to the fact that 
our study was conducted in a tertiary referral center 
and may not reflect the majority of hypertensive pa-
tients. 
In conclusion, the most commonly prescribed anti-
hypertensives in our setting are the ACEIs and CCBs 
which is in keeping with the prevailing international 
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